Drugs / CG200745 PPA
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02737462 | Jun 2016 → Dec 2022 | myelodysplastic syndrome | CrystalGenomics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02737228 | Mar 2016 → Aug 2019 | malignant pancreatic neoplasm | CrystalGenomics, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG200745 PPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02737462 ↗ |
| Known as | CG200745 PPA (phosphoric acid) | “CG200745 PPA (phosphoric acid)” NCT02737462 ↗ |
| Route | Intravenous | “CG200745 PPA IV every week three times per cycle (4 weeks)” NCT02737228 ↗ |